EVFM (Evofem Biosciences) 12-1 Month Momentum %: -28.57% (As of Sep. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Evofem Biosciences 12-1 Month Momentum %?

Evofem Biosciences EVFM 12-1 Month Momentum % is -28.57% as of Sep. 02, 2026. The stock has 5 warning signs investors should review. Among 1,358 Biotechnology companies, Evofem Biosciences ranks worse than 54.49% on this metric.

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-02), Evofem Biosciences's 12-1 Month Momentum % is -28.57%.

The industry rank for Evofem Biosciences's 12-1 Month Momentum % or its related term are showing as below:

EVFM's 12-1 Month Momentum % is ranked worse than
54.49% of 1358 companies
in the Biotechnology industry
Industry Median: -22.815 vs EVFM: -28.57

Evofem Biosciences  (OTCPK:EVFM) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Evofem Biosciences 12-1 Month Momentum % Related Terms

EVFM vs BZYR, ZVSA, RMTG: 12-1 Month Momentum % Comparison

For the Biotechnology subindustry, Evofem Biosciences's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evofem Biosciences 12-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evofem Biosciences's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Evofem Biosciences's 12-1 Month Momentum % falls into.


Evofem Biosciences  (OTCPK:EVFM) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 12-1 Month Momentum % →
What does a 12-1 Month Momentum % of -28.57% mean?
Evofem Biosciences (EVFM) has a 12-1 Month Momentum % of -28.57% as of Sep. 02, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Evofem Biosciences and its competitors. According to the industry distribution chart, Evofem Biosciences ranks #740 out of 1358 companies in the Biotechnology industry, placing it in the top 54.5%.
Is Evofem Biosciences' 12-1 Month Momentum % too high?
Evofem Biosciences' current 12-1 Month Momentum % is -28.57%. Based on the distribution chart, Evofem Biosciences ranks #740 out of 1358 companies in the Biotechnology industry, which is below the industry midpoint.
How does Evofem Biosciences' 12-1 Month Momentum % compare to BZYR and ZVSA?
According to the Biotechnology industry distribution chart, Evofem Biosciences ranks #740 out of 1358 companies for 12-1 Month Momentum %. This places Evofem Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Evofem Biosciences and its competitors. Evofem Biosciences's current 12-1 Month Momentum % is -28.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evofem Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Evofem Biosciences (EVFM) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 20% below its estimated fair value. The current 12-1 Month Momentum % is -28.57%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Evofem Biosciences (EVFM), the current 12-1 Month Momentum % is -28.57% as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evofem Biosciences Business Description

Address 7770 Regents Road, Suite 113-618, San Diego, CA, USA, 92122
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.